Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?

Neuroscience Letters

Volumn 596, Issue , 2015, Pages 90-107

  Carozzi, V A ^a   Canta, A ^a   Chiorazzi, A ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Chemotherapy drugs; Dorsal Root Ganglia; Neuropathic pain; Peripheral nerves; Peripheral neurotoxicity

Indexed keywords

BORTEZOMIB; CASPASE; CELL NUCLEUS DNA; CISPLATIN; COPPER TRANSPORTER 1; GLUTAMIC ACID; ION CHANNEL; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 2; OXALIPLATIN; PACLITAXEL; PROTEIN KINASE C; SEROTONIN TRANSPORTER; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

BLOOD BRAIN BARRIER; BRAIN MITOCHONDRION; CALCIUM SIGNALING; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; DNA REPAIR; GLIA CELL; HUMAN; INFLAMMATION; MEMBRANE TRANSPORT; NERVE CELL PLASTICITY; NERVE FIBER TRANSPORT; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SENSORY NERVE CELL; SHORT SURVEY; CHEMICALLY INDUCED; DNA DAMAGE; DRUG EFFECTS; GLIA; METABOLISM; MITOCHONDRION; NEURALGIA; PATHOLOGY; PHYSIOLOGY; SATELLITE CELL; SCHWANN CELL; SIGNAL TRANSDUCTION; SPINAL GANGLION;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; GANGLIA, SPINAL; GLUTAMIC ACID; HUMANS; ION CHANNELS; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; NEURALGIA; NEUROGLIA; OXIDATIVE STRESS; PERIPHERAL NERVOUS SYSTEM DISEASES; SATELLITE CELLS, PERINEURONAL; SCHWANN CELLS; SENSORY RECEPTOR CELLS; SIGNAL TRANSDUCTION;

EID: 84929658614     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.10.014     Document Type: Review

References (220)

1. Park S.B., Krishnan A.V., Lin C.S., Goldstein D., Friedlander M., Kiernan M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr. Med. Chem. 2008, 15:3081-3094.
2. Jaggi A.S., Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012, 291:1-9.
3. Allen D.T., Kiernan J.A. Permeation of proteins from the blood into peripheral nerves and ganglia. Neuroscience 1994, 59:755-764.
4. Strumberg D.D., Brügge S., Korn M.W., Koeppen S., Ranft J., Scheiber G., Reiners C., Möckel C., Seeber S., Scheulen M.E. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol. 2002, 13:229-236.
5. Cavaletti G., Cavalletti E., Oggioni N., Sottani C., Minoia C., D'Incalci M., Zucchetti M., Marmiroli P., Tredici G. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2003, 21:389-393.
6. Chaudhry V., Cornblath D.R., Corse A., Freimer M., Simmons-O'Brien E., Vogelsang G. Thalidomide-induced neuropathy. Neurology 2012, 59:1872-1875.
7. Isoardo G., Bergui M., Durelli L., Barbero P., Boccadoro M., Bertola A., Ciaramitaro P., Palumbo A., Bergamasco B., Cocito D. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol. Scand. 2004, 109:188-193.
8. Theiss C., Meller K. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res. 2000, 299:213-224.
9. Poruchynsky M.S., Sackett D.L., Robey R.W., Ward Y., Annunziata C., Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008, 7:940-949.
10. Macfarlane B.V., Wright A., Benson H.A. Reversible blockade of retrograde axonal transport in the rat sciatic nerve by vincristine. J. Pharm. Pharmacol. 1997, 49:97-101.
11. Flatters S.J.L., Bennett G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006, 122:247-257.
12. Melli G., Taiana M., Camozzi F., Triolo D., Podini P., Quattrini A., Taroni F., Lauria G. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp. Neurol. 2008, 214:276-284.
13. Broyl A., Corthals S.L., Jongen J.L., van der Holt B., Kuiper R., de Knegt Y., van Duin M., el Jarari L., Bertsch U., Lokhorst H.M., Durie B.G., Goldschmidt H., Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010, 11:1057-1065.
14. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., Marmiroli P., Bossi M., Oggioni N., D'Incalci M., De Coster R. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp. Neurol. 2007, 204:317-325.
15. Kirchmair R., Tietz A.B., Panagiotou E., Walter D.H., Silver M., Yoon Y.S., Schratzberger P., Weber A., Kusano K., Weinberg D.H., Ropper A.H., Isner J.M., Losordo D.W. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol. Ther. 2007, 15:69-75.
16. Kirchmair R., Walter D.H., Ii M., Rittig K., Tietz A.B., Murayama T., Emanueli C., Silver M., Wecker A., Amant C., Schratzberger P., Yoon Y.S., Weber A., Panagiotou E., Rosen K.M., Bahlmann F.H., Adelman L.S., Weinberg D.H., Ropper A.H., Isner J.M., Losordo D.W. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 2002, 111:2662-2670.
17. Ling B., Authier N., Balayssac D., Eschalier A., Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 2007, 128:225-234.
18. Nieto F.R., Entrena J.M., Cendán C.M., Pozo E.D., Vela J.M., Baeyens J.M. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Brain 2008, 137:520-531.
19. Ghelardini C., Desaphy J.F., Muraglia M., Corbo F., Matucci R., Dipalma A., Bertucci C., Pistolozzi M., Nesi M., Norcini M., Franchini C., Camerino D.C. Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models. Neuroscience 2010, 169:863-873.
20. Siau C., Bennett G.J. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth. Analg. 2006, 102:1485-1490.
21. Descoeur J., Pereira V., Pizzoccaro A., Francois A., Ling B., Maffre V., Couette B., Busserolles J., Courteix C., Noel J., Lazdunski M., Eschalier A., Authier N., Bourinet E. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 2011, 3:266-278.
22. Ta L.E., Espeset L., Podratz J., Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006, 27:992-1002.
23. Ta L.E., Bieber A.J., Carlton S.M., Loprinzi C.L., Low P.A., Windebank A.J. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol. Pain 2010, 6:15.
24. Anand U., Otto W.R., Anand P. Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons. Mol. Pain 2010, 6:82.
25. Quartu M., Carozzi V.A., Dorsey S.G., Serra M.P., Poddighe L., Picci C., Boi M., Melis T., Del Fiacco M., Meregalli C., Chiorazzi A., Renn C.L., Cavaletti G., Marmiroli P. Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. Biomed. Res. Int. 2014, 2014:180428.
26. Pascual D., Goicoechea C., Burgos E., Martín M.I. Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats. Pharmacol. Biochem. Behav. 2010, 95:331-337.
27. Carozzi V.A., Chiorazzi A., Canta A., Lapidus R.G., Slusher B.S., Wozniak K.M., Cavaletti G. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox. Res. 2010, 17:380-391.
28. Rutkove M. Effects of temperature on neuromuscular electrophysiology. Muscle Nerve 2001, 24:867-882.
29. Scuteri A., Galimberti A., Ravasi M., Pasini S., Donzelli E., Cavaletti G., Tredici G. NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci. Lett. 2010, 486:141-145.
30. Siau C., Xiao W., Bennett G.J. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp. Neurol. 2006, 201:507-514.
31. Ledeboer A., Jekich B.M., Sloane E.M., Mahoney J.H., Langer S.J., Milligan E.D., Martin D., Maier S.F., Johnson K.W., Leinwand L.A., Chavez R.A., Watkins L.R. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. 2007, 21:686-698.
32. Mangiacavalli S., Corso A., De Amici M., Varettoni M., Alfonsi E., Lozza A., Lazzarino M. Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. Br. J. Haematol. 2010, 149:916-918.
33. Joseph E.K., Chen X., Bogen O., Levine J.D. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J. Pain 2008, 9:463-472.
34. Kim H.K., Zhang Y.P., Gwak Y.S., Abdi S. Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology 2010, 112:432-439.
35. Wang H.T., Liu Z.G., Yang W., Liao A.J., Zhang R., Wu B., Wang H.H., Yao K., Li Y.C. Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione. Zhonghua Xue Ye Xue Za Zhi 2011, 32:107-111.
36. Muthuraman A., Jaggi A.S., Singh N., Singh D. Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine induced painful neuropathy in rats. Eur. J. Pharmacol. 2008, 587:104-111.
37. Mollman J.E. Cisplatin neurotoxicity. N. Engl. J. Med. 1990, 322:126-127.
38. Cavaletti G., Fabbrica D., Minoia C., Frattola L., Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann. Oncol. 1998, 9:443-447.
39. McDonald E.S., Windebank A.J. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signalling. Neurobiol. Dis. Mar. 2002, 2:220-233.
40. Price C.J., Hoyda T.D., Ferguson A.V. The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist 2008, 14:182-194.
41. Cavaletti G., Marzorati L., Bogliun G., Colombo N., Marzola M., Pittelli M.R., Tredici G. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69:203-207.
42. Mollman J.E., Glover D.J., Hogan W.M., Furman R.E. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1998, 61:2192-2195.
43. Lo Monaco M., Milone M., Batocchi A.P., Padua L., Tonali D.P. Cisplatin neuropathy: clinical course and neurophysiological findings. J. Neurol. 1992, 239:199-204.
44. Albers J., Chaudhry V., Cavaletti G., Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev. 2001, 24:CD005228.
45. Lebwohl D., Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer 1998, 34:522-534.
46. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
47. Krarup-Hansen A., Helweg-Larsen S., Schmalbruch H., Rørth M., Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007, 130:1076-1088.
48. Krarup-Hansen A., Rietz B., Krarup C., Heydorn K., Rørth M., Schmalbruch H. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol. Appl. Neurobiol. 1999, 4:12-18.
49. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269-1275.
50. Englander E.W. DNA damage response in peripheral nervous system: coping with cancer therapy-induced DNA lesions. DNA Rep. (Amst) 2013, 12:685-690.
51. Cavaletti G., Tredici G., Pizzini G., Minoia A. Tissue platinum concentrations and cisplatin schedules. Lancet 1990, 336:1003.
52. Gregg R.W., Molepo J.M., Monpetit V.J., Mikael N.Z., Redmond D., Gadia M., Stewart D.J. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J. Clin. Oncol. 1992, 10:795-803.
53. Cece R., Petruccioli M.G., Cavaletti G., Barajon I., Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol. Histopathol. 1995, 10:837-845.
54. Dzagnidze A., Katsarava Z., Makhalova J., Liedert B., Yoon M.S., Kaube H., Limmroth V., Thomale J. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci. 2007, 27:9451-9457.
55. Yang Z., Faustino P.J., Andrews P.A., Monastra R., Rasmussen A.A., Ellison C.D., Cullen K.J. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother. Pharmacol. 2000, 46:255-262.
56. Fan S., Smith M.L., Rivet D.J., Duba D., Zhan Q., Kohn K.W., Fornace A.J., O'Connor P.M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995, 55:1649-1654.
57. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cis-platin sensitivity of human cells. Cancer Res. 2002, 62:3899-4902.
58. Köberle B., Grimaldi K.A., Sunters A., Hartley J.A., Kelland L.R., Masters J.R. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer 1997, 70:551-555.
59. Mc Donald E.S., Randon K.R., Knight A., Windebank A.J. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol. Dis. 2005, 18:305-313.
60. Ciarimboli G. Membrane transporters as mediators of cisplatin effects and side effects. Scientifica (Cairo) 2012, 2012:473829.
61. Jordan P., Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci. 2000, 57:1229-1235.
62. Nouspikel T., Hanawalt P.C. DNA repair in terminally differentiated cells. DNA Rep. (Amst) 2002, 1:59-75.
63. Jiang Y., Guo C., Vasko M.R., Kelley M.R. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res. 2008, 68:6425-6434.
64. Clayton D.A. Replication and transcription of vertebrate mitochondrial DNA. Annu. Rev. Cell Biol. 1991, 7:453-478.
65. Podratz J.L., Knight A.M., Ta L.E., Staff N.P., Gass J.M., Genelin K., Schlattau A., Lathroum L., Windebank A.J. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol. Dis. 2011, 41:661-668.
66. Croteau D.L., Stierum R.H., Bohr V.A. Mitochondrial DNA repair pathways. Mutat. Res. 1999, 434:137-148.
67. Grunberg S.M., Sonka S., Stevenson L.L., Muggia F.M. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother. Pharmacol. 1989, 25:62-64.
68. Züchner S., Mersiyanova I.V., Muglia M., Bissar-Tadmouri N., Rochelle J., Dadali E.L., Zappia M., Nelis E., Vance J.M. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2. Nat. Genet. 2004, 36:449-451.
69. Shishkin V., Potapenko E., Kostyuk E., Girnyk O., Voitenko N., Kostyuk P. Role of mitochondria in intracellular calcium signaling in primary and secondary sensory neurones of rats. Cell Calcium 2002, 32:121-130.
70. Joseph E.K., Levine J.D. Caspase signalling in neuropathic and inflammatory pain in the rat. Eur. J. Neurosci. 2004, 20:2896-2902.
71. Chung.M. The role of reactive oxygen species (ROS) in persistent pain. Mol. Interv. 2004, 4:248-250.
72. Pan H., Mukhopadhyay P., Rajesh M., Patel V., Bukhopadhyay B., Gao B., Hasko G., Pacher P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther. 2009, 328:708-714.
73. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst. 2008, 13:27-46.
74. Miller K.E., Sheetz M.P. Axonal mitochondrial transport and potential are correlated. J. Cell Sci. 2004, 117:2791-2804.
75. Cavaletti G., Minoia C., Schieppati M., Tredici G. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29:771-776.
76. Favilli F., Marraccini P., Iantomasi T., Vincenzini M.T. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br. J. Nutr. 1997, 78:293-300.
77. Antunes L.M., Araujo M.C.P., D'Arc J., Darin C., Bianchi M.L.P. Effects of the antioxidants curcumin and vitamin C on cisplatin-induced clastogenesis in Wistar rat bone marrow cells. Mutat. Res. 2000, 465:131-137.
78. Cavaletti G., Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur. J. Cancer 2002, 38:1832-1837.
79. Park S.A., Choi K.S., Bang J.H., Huh K., Kim S.U. Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand. J. Neurochem. 2000, 75:946-953.
80. Zhang Y., Fujita N., Tsuruo T. Caspase-mediated cleavage of p21 Wafl/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999, 18:1131-1138.
81. Madiraju P., Pande S.V., Prentki M., Madiraju S.R.M. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 2009, 4:399-403.
82. Horvath P., Szilvassy J., Nemeth J., Peitl B., Szilasi M., Szilvassy Z. Decreased sensory neuropeptide release in isolated bronchi of rats with cisplatin-induced neuropathy. Eur. J. Pharmacol. 2005, 507:247-252.
83. Gately D.P., Howell S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer 1993, 67:1171-1176.
84. Liu J.J., McKeage M.J. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr. Cancer Drug Targets 2012, 12:962-986.
85. Nose Y., Rees E.M., Thiele D.J. Structure of the Ctr1 copper trans'PORE'ter reveals novel architecture. Trends Biochem. Sci. 2006, 31:604-607.
86. Holzer A.K., Katano K., Klomp L.W., Howell S.B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 2004, 10:6744-6749.
87. Liu J.J., Jamieson S.M., Subramaniam J., Jong N.N., Mercer J.F., McKeage M.J. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother. Pharmacol. 2009, 64:847-856.
88. Jamieson S.M.F., Liu J., Connor B., McKeage M.J. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother. Pharmacol. 2005, 56:391-399.
89. Crisponi V.M., Nurchi D., Fanni C., Gerosa S., Nemolato G. Copper-related diseases: from chemistry to molecular pathology. Coord. Chem. Rev. 2010, 254:876-889.
90. Ciarimboli G., Deuster D., Knief A., Sperling M., Holtkamp M., Edemir B., Pavenstädt H.C., Zehnhoff-Dinnesen A., Schinkel A.H., Koepsell H., Jürgens H., Schlatter E. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176:1169-1180.
91. Cavaletti G., Ceresa C., Nicolini G., Marmiroli P. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity. Anticancer Res. 2014, 34:483-486.
92. Sprowl J.A., Ciarimboli G., Lancaster C.S., Giovinazzo H., Gibson A.A., Du G., Janke L.J., Cavaletti G., Shields A.F., Sparreboom A. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:11199-11204.
93. +/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem. Pharmacol. 2011, 81:563-568.
94. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 1998, 25:4-12.
95. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Ann. Pharmacother. 2005, 39:128-135.
96. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18(16):2938-2947.
97. Land S.R., Kopec J.A., Cecchini R.S., Ganz P.A., Wieand H.S., Colangelo L.H., Murphy K., Bearden J.D., Colman L.K., Lanier K.S., Pajon E.R., Wolmark N. Neurotoxicity from oxaliplatin, combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J. Clin. Oncol. 2007, 25:2205-2211.
98. Pietrangeli A., Leandri M., Terzoli E., Jandolo B., Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur. Neurol. 2006, 56:13-16.
99. Egashira N., Hirakawa S., Kawashiri T., Yano T., Ikesue H., Oishi R. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J. Pharmacol. Sci. 2010, 112:473-476.
100. + channel kinetics on rat sensory neurons. Eur. J. Pharmacol. 2000, 406:25-32.
101. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 2001, 85:2293-2297.
102. Webster R.G., Brain K.L., Wilson R.H., Grem J.L., Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 2005, 146:1027-1039.
103. Krishnan A.V., Goldstein D., Friedlander M., Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51-60.
104. Nakayama J., Yamamoto N., Arinami T. Failure to find evidence for association between voltage-gated sodium channel gene SCN2A variants and febrile seizures in humans. Neurosci. Lett. 2002, 329:249-251.
105. Argyriou A.A., Cavaletti G., Antonacopoulou A., Genazzani A.A., Briani C., Bruna J., Terrazzino S., Velasco R., Alberti P., Campagnolo M., Lonardi S., Cortinovis D., Cazzaniga M., Santos C., Psaromyalou A., Angelopoulou A., Kalofonos H.P. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer 2013, 119:3570-3577.
106. Kagiava A., Tsingotjidou A., Emmanouilides C., Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008, 29:1100-1106.
107. Sittl R., Carr R.W., Fleckenstein J., Grafe P. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. Neurotoxicology 2010, 31:694-700.
108. Schulze C., McGowan M., Jordt S.E., Ehrlich B.E. Prolonged oxaliplatin exposure alters intracellular calcium signaling: a new mechanism to explain oxaliplatin-associated peripheral neuropathy. Clin. Colorectal Cancer 2011, 10:126-133.
109. Gauchan P., Andoh T., Kato A., Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci. Lett. 2009, 458:93-95.
110. Wahl P., Foged C., Tullin S., Thomsen C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol. Pharmacol. 2001, 59:9-15.
111. Shimizu I., Iida T., Horiuchi N., Caterina M.J. 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J. Pharmacol. Exp. Ther. 2005, 314:1378-1385.
112. Nassini R., Gees M., Harrison S., De Siena G., Materazzi S., Geppetti P. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011, 152:1621-1631.
113. Bessac B.F., Sivula M., von Hehn C.A., Escalera J., Cohn L., Jordt S.E. TRPA1 is a major oxidant sensor in murine airway sensory neurons. J. Clin. Investig. 2008, 118:1899-1910.
114. Karashima Y., Talavera K., Everaerts W., Janssens A., Kwan K.Y., Vennekens R., Nilius B., Voets T. TRPA1 acts as a cold sensor in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1273-1278.
115. Lim S.C., Choi J.E., Kang H.S., Han S.I. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int. J. Cancer 2010, 126:1582-1595.
116. Taylor-Clark T.E., Ghatta S., Bettner W., Undem B.J. Nitrooleic acid, an endogenous product of nitrative stress, activates nociceptive sensory nerves via the direct activation of TRPA1. Mol. Pharmacol. 2009, 75:820-829.
117. del Camino D., Murphy S., Heiry M., Barrett L.B., Earley T.J., Cook C.A., Petrus M.J., Zhao M., D'Amours M., Deering N., Brenner G.J., Costigan M., Hayward N.J., Chong J.A., Fanger C.M., Woolf C.J., Patapoutian A., Moran M.M. TRPA1 contributes to cold hypersensitivity. J. Neurosci. 2010, 30:15165-15174.
118. Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp. Neurol. 2011, 232:154-161.
119. Norcini M., Vivoli E., Galeotti N., Bianchi E., Bartolini A., Ghelardini C. Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain 2009, 146:141-147.
120. Holmes J., Stanko J., Varchenko M. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a wistar rat model. Toxicol. Sci. 1998, 46:342-351.
121. Safaei R., Adams P.L., Maktabi M.H., Mathews R.A., Howell S.B. The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J. Inorg. Biochem. 2012, 110:8-17.
122. Raghavendra V., Tanga F., DeLeo J.A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 2003, 306:624-630.
123. Zhang T., Zhang J., Shi J., Feng Y., Sun Z.S., Li H. Antinociceptive synergistic effect of spinal mGluR2/3 antagonist and glial cells inhibitor on peripheral inflammation-induced mechanical hypersensitivity. Brain Res. Bull. 2009, 79:219-223.
124. Di Cesare Mannelli L., Zanardelli M., Failli P., Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J. Pain 2012, 13:276-284.
125. Di Cesare Mannelli L., Pacini A., Matera C., Zanardelli M., Mello T., De Amici M., Dallanoce C., Ghelardini C. Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacology 2014, 79:37-48.
126. Yoon S.Y., Robinson C.R., Zhang H., Dougherty P.M. Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. J. Pain 2013, 14:205-214.
127. Postma T.J., Benard B.A., Huijgens P.C., Ossenkoppele G.J., Heimans J.J. Long-term effects of vincristine on the peripheral nervous system. J. Neurooncol. 1993, 15:23-27.
128. Casey E.B., Jellife A.M., Le Quesne P.M., Millett Y.L. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973, 96:69-86.
129. Lobert S., Vulevic B., Correia J.J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996, 35:6806-6814.
130. Tanner K.D., Levine J.D., Topp K.S. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J. Comp. Neurol. 1998, 395:481-492.
131. Tanner K.D., Reichling D.B., Levine J.D. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J. Neurosci. 1998, 18:6480-6491.
132. Latremoliere A., Woolf C.J. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain 2009, 10:895-926.
133. Besse D., Lombard M.C., Zajac J.M., Roques B.P., Besson J.M. Pre- and postsynaptic location of mu, delta and kappa opioid receptors in the superficial layers of the dorsal horn of the rat spinal cord. Prog. Clin. Biol. Res. 1990, 328:183.
134. Zadina J.E. Isolation and distribution of endomorphins in the central nervous system. J. Pharmacol. 2002, 89:203-208.
135. Sanderson Nydahl K., Skinner K., Julius D., Basbaum A.I. Colocalization of endomorphin-2 and substance P in primary afferent nociceptors and effects of injury: a light and electron microscopic study in the rat. Eur. J. Neurosci. 2004, 19:1789-1799.
136. Grass S., Wiesenfeld-Hallin Z., Xu X.J. The effect of intrathecal endomorphin-2 on the flexor reflex in normal, inflamed and axotomized rats: reduced effect in rats with autotomy. Neuroscience 2000, 98:339-344.
137. Yang Y., Zhang Y.G., Lin G.A., Xie H.Q., Pan H.T., Huang B.Q., Liu J.D., Liu H., Zhang N., Li L., Chen J.H. Spinal changes of a newly isolated neuropeptide endomorphin-2 concomitant with vincristine-induced allodynia. PLOS ONE 2014, 9:e89583.
138. Wang C.H., Cherng W.J., Yang N.I., Hsu C.M., Yeh C.H. Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294:811-818.
139. Thibault K., Calvino B., Rivals I., Marchan F., Dubacq S., McMahon S.B., Pezet S. Molecular mechanisms underlying the enhanced analgesic effect of oxycodone compared to morphine in chemotherapy-induced neuropathic pain. PLOS ONE 2014, 9:e91297.
140. Falk E. Eukodal, ein neues Narkotikum. Munch Med. Wochens 1917, 20:3812384.
141. Thibault K., Rivals I., M'Dahoma S., Dubacq S., Pezet S., Calvino B. Structural and molecular alterations of primary afferent fibres in the spinal dorsal horn in vincristine-induced neuropathy in rat. J. Mol. Neurosci. 2013, 51:880-892.
142. Ibi D., Nitta A., Ishige K., Cen X., Ohtakara T., Nabeshima T., Ito Y. Piccolo knockdown-induced impairments of spatial learning and long-term potentiation in the hippocampal CA1 region. Neurochem. Int. 2010, 56:77-83.
143. Xiao W.H., Bennett G.J. Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine. Pain 2008, 135:262-270.
144. Watkins L.R., Maier S.F. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J. Intern. Med. 2005, 257:139-155.
145. Ji X.T., Qian N.S., Zhang T., Li J.M., Li X.K., Wang P., Zhao D.S., Huang G., Zhang L., Fei Z., Jia D., Niu L. Spinal astrocytic activation contributes to mechanical allodynia in a rat chemotherapy-induced neuropathic pain model. PLOS ONE 2013, 8:e60733.
146. Chang D.T., Honick A.S., Reynolds I.J. Mitochondrial trafficking to synapses in cultured primary cortical neurons. J. Neurosci. 2006, 26:7035-7045.
147. Virmani A., Gaetani F., Binienda Z. Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine. Ann. N. Y. Acad. Sci. 2005, 21053:183-191.
148. Gradinaru D., Minn A.L., Artur Y., Minn A., Heydel J.M. Effect of oxidative stress on UDP-glucuronosyltransferases in rat astrocytes. Toxicol. Lett. 2012, 213:316-324.
149. Christoph T., Schiene K., Englberger W., Parsons C.G., Chizh B.A. The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. Neuropharmacology 2006, 51:12-17.
150. Qureshi A.A., Hosoi J., Xu S., Takashima A., Granstein R.D., Lerner E.A. Langerhans cells express inducible nitric oxide synthase and produce nitric oxide. J. Investig. Dermatol. 1996, 107:815-821.
151. Deng L., Ding W., Granstein R.D. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J. Investig. Dermatol. 2003, 121:1060-1065.
152. Torii H., Yan Z., Hosoi J., Granstein R.D. Expression of neurotrophic factors and neuropeptide receptors by Langerhans cells and the Langerhans cell-like cell line XS52 further support for a functional relationship between Langerhans cells and epidermal nerves. J. Investig. Dermatol. 1997, 109:586-591.
153. Jaggi A.S., Singh N. Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats. Eur. J. Pharmacol. 2010, 648:102-109.
154. Palm F., Mössner R., Chen Y., Gerlach M., Bischofs S., Riederer P., Lesch K.P., Sommer C. Reduced thermal hyperalgesia and enhanced peripheral nerve injury after hind paw inflammation in mice lacking the serotonin-transporter. Eur. J. Pain 2008, 12:790-797.
155. Eide P.K., Hole K. The role of 5-hydroxytryptamine (5-HT) receptor subtypes and plasticity in the 5-HT systems in the regulation of nociceptive sensitivity. Cephalalgia 1993, 13:75-85.
156. Moalem G., Graefe P., Tracey D.J. Chemical mediators enhance the excitability of unmyelinated sensory axons in normal and injured peripheral nerve of the rat. Neuroscience 2005, 134:1399-1411.
157. Suzuki R., Rygh L.J., Dickenson A.H. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol. Sci. 2004, 25:613-617.
158. Kim D.K., Tolliver T.J., Huang S.J., Martin B.J., Andrews A.W., Wichems C., Holmes A., Lesch K.P., Murphy D.L. Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology 2005, 49:798-810.
159. Hansen N., Uçeyler N., Palm F., Zelenka M., Biko L., Lesch K.P., Gerlach M., Sommer C. Serotonin transporter deficiency protects mice from mechanical allodynia and heat hyperalgesia in vincristine neuropathy. Neurosci. Lett. 2011, 495:93-97.
160. Barzegar-Fallah A., Alimoradi H., Mehrzadi S., Barzegar-Fallah N., Zendedel A., Abbasi A., Dehpour A.R. The neuroprotective effect of tropisetron on vincristine-induced neurotoxicity. Neurotoxicology 2014, 41:1-8.
161. Vega L., Munoz E., Calzado M.A., Lieb K., Candelario-Jalil E., Gschaidmeir H. The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem. Pharmacol. 2005, 70:369-380.
162. Kantrow S.P., Gierman J.L., Jaligam V.R., Zhang P., Piantadosi C.A., Summer W.R. Regulation of tumor necrosis factor cytotoxicity by calcineurin. FEBS Lett. 2000, 483:119-124.
163. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000, 1:11-21.
164. Tari C., Fournier N., Briand C. Action of vinca alkaloides on calcium movements through mitochondrial membrane. Pharmacol. Res. Commun. 1986, 18:519-528.
165. 2+ transients that modulate secretion. Nat. Cell Biol. 2000, 2:57-61.
166. Kannurpatti S.S., Joshi P.G., Joshi N.B. Calcium sequestering ability of mitochondria modulates influx of calcium through glutamate receptor channel. Neurochem. Res. 2000, 25:1527-1536.
167. Jaggi A.S., Singh N. Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats. Food Chem. Toxicol. 2012, 50:1295-1301.
168. Zhuang Z.Y., Gerner P., Woolf C.J., Ji R.R. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 14:149-159.
169. Mayer D.J., Mao J., Holt J., Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7731-7736.
170. Derry W., Wilson L., Jordan M. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995, 34:2203-2211.
171. Dumontet C., Jordan M. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9:790e803.
172. Jordan M., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
173. Quasthoff S., Hartung H. Chemotherapy-induced peripheral neuropathy. J. Neurol. 2002, 249:9-17.
174. Dougherty P.M., Cata J.P., Cordella J.V., Burton A., Weng H.R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 109:132-142.
175. Argyriou A., Koltzenburg M., Polychronopoulos P., Papapetropoulos S., Kalofonos H. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit. Rev. Oncol. Hematol. 2008, 66:218-228.
176. Sahenk Z., Barohn R., New P., Mendell J.R. Taxol neuropathy, electrodiagnostic and sural nerve biopsy findings. Arch. Neurol. 1994, 51:726-729.
177. Scuteri A., Nicolini G., Miloso M., Bossi M., Cavaletti G., Windebank A., Tredici G. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res. 2006, 26:1065-1070.
178. Yang I., Siddique R., Hosmane S., Thakor N., Höke A. Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration. Exp. Neurol. 2009, 218:124-128.
179. Martin L.J., Gertz B., Pan Y., Price A.C., Molkentin J.D., Chang Q. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp. Neurol. 2009, 218:333-346.
180. Bernardi P., Krauskopf A., Basso E., Petronilli V., Blachly-Dyson E., Di Lisa F., Forte M.A. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 2006, 273:2077-2099.
181. 2+ signals by opening the mitochondrial permeability transition pore. J. Biol. Chem. 2002, 277:6504-6510.
182. 2+ release. J. Biol. Chem. 2005, 280:715-721.
183. Andrè N., Braguer D., Brasseur G., Goncalves A., Lemesle-Meunier D., Guise S., Jordan M.A., Briand C. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res. 2000, 60:5349-5353.
184. Carré M., André N., Carles G., Borghi H., Brichese L., Briand C., Braguer D. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J. Biol. Chem. 2002, 277:33664-33669.
185. Rodi D., Janes R., Sanganee H., Holton R., Wallace B., Makowski L. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J. Mol. Biol. 1999, 285:197-203.
186. Jin H., Flatters S., Xiao W., Mulhern H., Bennett G. Prevention of paclitaxel evoked painful peripheral neuropathy by acetyl-l-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp. Neurol. 2008, 210:229-237.
187. Xiao W., Boroujerdi A., Bennett G.J., Luo Z.D. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007, 144:714-720.
188. Matsumoto M., Inoue M., Hald A., Xie W., Ueda H. Inhibition of paclitaxel induced A-fiber hypersensitization by gabapentin. J. Pharmacol. Exp. Ther. 2006, 318:735-740.
189. 2+ sensor 1-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18356-18361.
190. 2+ sensor-1 degradation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11103-11108.
191. Wang M., Davis A., Culver D., Wang Q., Powers J., Glass J. Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain J. Neurol. 2004, 127:671-679.
192. Amir R., Argoff C.E., Bennett G.J., Cummins T.R., Durieux M.E., Gerner P. The role of sodium channels in chronic inflammatory and neuropathic pain. J. Pain 2006, 7:S1-S29.
193. Zhang Y.Y., Li G., Che H., Sun H.Y., Li X., Au W.K., Xiao G.S., Wang Y., Li G.R. Characterization of functional ion channels in human cardiac c-kit+ progenitor cells. Basic Res. Cardiol. 2014, 109:407.
194. Basbaum A.I., Bautista D.M., Scherrer G., Julius D. Cellular and molecular mechanisms of pain. Cell 2009, 139:267-284.
195. Alessandri-Haber N., Dina O.A., Joseph E.K., Reichling D.B., Levine J.D. Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J. Neurosci. 2008, 28:1046-1057.
196. Materazzi S., Fusi C., Benemei S., Pedretti P., Patacchini R., Nilius B., Prenen J., Creminon C., Geppetti P., Nassini R. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers Arch. 2012, 463:561-569.
197. Peters C.M., Jimenez-Andrade J.M., Jonas B.M. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp. Neurol. 2007, 203:42-54.
198. Nishida K., Kuchiiwa S., Oiso S., Futagawa T., Masuda S., Takeda Y., Yamada K. Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy. Cancer Sci. 2008, 99:1618-1625.
199. Cata J.P., Weng H.R., Lee B.N., Reuben J.M., Dougherty P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006, 72:151-169.
200. Mohammad A.S., Maureen N.B., Ali R.J. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects. Am. J. Cancer Res. 2011, 1:913-924.
201. Kouroukis C.T., Baldassarre F.G., Haynes A.E., Imrie K., Reece D.E., Cheung M.C. Bortezomib in multiple myeloma: a practice guideline. Clin. Oncol. 2014, 26:110-119.
202. Skrott Z., Cvek B. Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. Crit. Rev. Oncol. Hematol. 2014, (in press).
203. Meregalli C., Ceresa C., Canta A., Carozzi V.A., Chiorazzi A., Sala B., Oggioni N., Lanza M., Letari O., Ferrari F., Avezza F., Marmiroli P., Caselli G., Cavaletti G.G. CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J. Pain Res. 2012, 5:151-167.
204. Cavaletti G., Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007, 92:1308-1310.
205. Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593-1599.
206. Giannoccaro M.P., Donadio V., Gomis Pèrez C., Borsini W., Di Stasi V., Liguori R. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurol. Sci. 2011, 32:361-363.
207. Curran M.P., McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009, 69:859-888.
208. Seki N., Toh U., Sayers T.J., Fujii T., Miyagi M., Akagi Y., Kusukawa J., Kage M., Shirouzu K., Yamana H. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol. Cancer Ther. 2010, 9:1842-1851.
209. Meregalli C., Chiorazzi A., Carozzi V.A., Canta A., Sala B., Colombo M., Oggioni N., Ceresa C., Foudah D., La Russa F., Miloso M., Nicolini G., Marmiroli P., Bennett D.L., Cavaletti G. Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle 2014, 13:612-621.
210. 2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005, 65:3828-3838.
211. Nakano A., Abe M., Oda A., Amou H., Hiasa M., Nakamura S., Miki H., Harada T., Fujii S., Kagawa K., Takeuchi K., Watanabe T., Ozaki S., Matsumoto T. Delayed treatment with vitamic C and N-acetyl-l-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib. In. J. Hematol. 2011, 93:727-735.
212. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Ann. Rev. Genet. 2009, 43:67-93.
213. Stemkowski P.L., Smith P.A. Sensory neurons, ion channels, inflammation and the onset of neuropathic pain. Can. J. Neurol. Sci. 2012, 39:416-435.
214. Chiorazzi A., Canta A., Meregalli C., Carozzi V., Sala B., Oggioni N., Monbaliu J., van de Velde H., Cavaletti G. Antibody against Tumor Necrosis Factor-α educes Bortezomib-induced allodynia in a rat model. Anticancer Res. 2013, 33:5453-5460.
215. Herder C., Lankisch M., Ziegler D., Rathmann W., Koenig W., Illig T., Doring A., Thorand B., Holle R., Giani G., Martin S., Meisinger C. Subclinical inflammation and diabetic polyneuropathy. Diabetes Care 2009, 32:680-682.
216. Papa L., Rockwell P. Persistent mitochondrial dysfunction and oxidative stress hinder neuronal cell recovery from reversible proteasome inhibition. Apoptosis 2008, 13:588-599.
217. Okouchi M., Ekshyyan O., Maracine M., Aw T.Y. Neuronal apoptosis in neurodegeneration. Antioxid. Redox Signal. 2007, 9:1059-1096.
218. Swerdlow R.H. Treating neurodegeneration by modifying mitochondria: potential solutions to a complex problem. Antioxid. Redox Signal. 2007, 9:1591-1604.
219. Du Z.X., Zhang H.Y., Meng X., Guan Y., Wang H.Q. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 2009, 9.
220. Urazaev A.K., Grossfeld R.M., Fletcher P.L., Speno H., Gafurov B.S., Buttram J.G., Lieberman E.M. Synthesis and release of N-acetylaspartylglutamate (NAAG) by crayfish nerve fibers: implications for axon-glia signalling. Neuroscience 2001, 106:237-247.